Malvinder Mohan Singh

Malvinder Mohan Singh is an Indian businessman. He was formerly the CEO of the now-defunct pharmaceutical firm Ranbaxy Laboratories. Along with his brother, Shivinder Mohan Singh, he has been charged in numerous cases of fraud related to his handling of the company.

As the head of Ranbaxy, Singh oversaw both a massively fraudulent operation aimed at deceiving the U.S. Food and Drug Administration (FDA) and other international health organisations as to the quality of the company's generic drug products, as well as the deception of the company's buyers when he mediated its sale to the Japanese drugmaker Daiichi Sankyo, in 2008.

In an unrelated incident, Singh was arrested in the early hours of 11 October 2019 near Ludhiana, pursuant to a further fraud case against him and his brother, who was also placed under arrest.

Early life and education Malvinder Mohan Singh is the grandson of Bhai Mohan Singh, who bought Ranbaxy Laboratories from its original founders in 1952.

Singh and his brother, Shivinder, attended the Doon School in Dehradun and later St. Stephen's College in Delhi. He went on to study at Duke University's Fuqua School of Business in Durham, North Carolina, where he earned his MBA.

Career Singh and his brother inherited their father's 33.5% stake in Ranbaxy upon his death in 1999, which placed them among the richest individuals in India. During his time with the company, Singh held the position of president of pharmaceuticals and eventually became CEO and managing director, in 2006. His tenure as head of the firm coincided with a period of intense, whistleblower-driven fraud investigations by the FDA, other world health organisations, as well as the U.S. Department of Justice (DOJ). Both brothers have denied the charges.